Performance · Recovery · Longevity

Shopping Cart (0)

Catalogue

Shop

Browse “Muscle/Performamnce, Recovery/Tissue, Weight Loss/Metabolic and Research Peptides“ and advanced wellness compounds. Prices are shown in South African Rand (ZAR).

Research peptides & wellness compounds

Select a product to view available quantities, specifications and regulatory status. Quantities, documentation and pricing are confirmed before dispatch.

Semaglutide 5mg (UPMAG 5)

Category:
Weight Loss / Metabolic / Longevity
SKU:
TRW-SEMA
Price:
R 850.00
{{variant.name}}:
{{opt.name}}
{{opt.value ? '' : opt.name}}
{{opt.value ? '' : opt.name}}
Description

TEST RUN WELLNESS UPMAG 5 | Semaglutide 5mg Self-Mix Vial

 

UPMAG 5 (Semaglutide 5mg) – Clinical-grade GLP-1 peptide for appetite regulation, fat loss, and glucose support. High-purity 5mg vial kit with 2ml bacteriostatic water.

 

Product Overview

UPMAG 5 is a Semaglutide 5mg self-mix vial. Semaglutide is a long-acting GLP-1 receptor agonist with 94% sequence homology to native human GLP-1. It selectively binds to and activates the GLP-1 receptor, the target for endogenous GLP-1, and achieves its prolonged half-life through albumin binding, which decreases renal clearance and protects the molecule from metabolic degradation. The 5mg vial is the most popular size for the initial 8-

 

How Semaglutide Works: GLP-1 Receptor Agonist Pathway 

Semaglutide reduces blood glucose through a glucose-dependent mechanism where it stimulates insulin secretion and lowers glucagon secretion. Beyond glycemic control, semaglutide acts on GLP-1 receptors in the brain, with direct effects on hypothalamic regions involved in homeostatic regulation of food intake.

 

Preclinical research shows that semaglutide engages both Gs- and Gq-dependent signaling pathways in GLP1R-expressing hindbrain neurons to drive weight loss. Semaglutide's weight-lowering effects are mediated not only by reduced food intake (hypophagia) but also by adipose tissue remodeling and browning. It also slows gastric emptying, further contributing to satiety and reduced caloric intake.

 

Body Recomposition Benefits

Semaglutide induces substantial reductions in body weight and fat mass, with modest fat-free mass (FFM) loss. A systematic review and meta-analysis found that semaglutide produced significant non-linear weight loss primarily due to fat mass reduction.

 

However, network meta-analysis data indicate that while semaglutide 2.4 mg weekly maximizes fat loss, it is among the least effective in preserving lean mass compared to other incretin therapies. Lean mass constituted approximately 35.2% of total weight lost with semaglutide in a recent meta-analysis.

 

Clinical strategies combining semaglutide with resistance exercise and nutritional support — particularly high-protein diets — may help preserve lean mass and optimize long-term outcomes. Some individuals have been shown to preserve or even increase lean soft tissue during treatment with semaglutide alongside supportive lifestyle strategies.

 

Titration Protocol

Semaglutide is administered as a once-weekly subcutaneous injection. The dose is escalated gradually over a minimum of 16 weeks to reach the maintenance dose of 2.4 mg once weekly, in order to reduce the likelihood of gastrointestinal symptoms. A standard escalation schedule is as follows:

· Weeks 1–4: 0.25 mg once weekly — starting dose, allows digestive adaptation
· Weeks 5–8: 0.5 mg once weekly — first escalation
· Weeks 9–12: 1.0 mg once weekly — second escalation
· Weeks 13–16: 1.7 mg once weekly — third escalation
· Week 17+: 2.4 mg once weekly — maintenance dose

Dose escalation should only proceed if the current dose is well tolerated. If gastrointestinal symptoms are pronounced, dose escalation may be delayed or the dose reduced to the previous level. The maintenance dose of 2.4 mg once weekly is the recommended target for weight management.

 

Combination Therapy

Combination therapies represent a promising strategy to enhance the efficacy of GLP-1 receptor agonism. The most advanced combination in clinical development is CagriSema, a fixed-dose combination of the long-acting amylin analogue cagrilintide (2.4 mg) and semaglutide (2.4 mg).

 

In the REDEFINE 1 trial, cagrilintide–semaglutide provided significant and clinically relevant body-weight reductions in adults with overweight or obesity compared with placebo. Co-agonism of GLP-1R and CTR/AMYR (calcitonin/amylin receptor) in the lateral dorsal tegmental nucleus produces additive effects on homeostatic and motivated feeding, which underlies the enhanced efficacy of the combination compared to either mono-agonist alone.

 

A systematic review and meta-analysis found that CagriSema achieves greater weight loss than semaglutide or placebo, but increases gastrointestinal adverse events, warranting careful tolerability monitoring. Other potential combinations include GLP-1 receptor agonists with SGLT-2 inhibitors or other central appetite modulators.

 

All combination approaches should be pursued under professional medical supervision.

 

Clinical Trial Record

Semaglutide has demonstrated robust efficacy across the STEP clinical development programme:

· STEP 1: Mean weight loss of 14.9% over 68 weeks with semaglutide 2.4 mg. 86% of participants achieved ≥5% weight loss, 69% achieved ≥10%, 50% achieved ≥15%, and 32% achieved ≥20%.
· STEP 2 (T2D): Mean weight loss of 9.6%.
· STEP 6 (Asian population): Mean weight loss of 9.6% with semaglutide 1.7 mg.
· STEP 11 (Asian population with BMI ≥25): Mean change in bodyweight of −16.0% with semaglutide 2.4 mg versus −3.1% with placebo at 68 weeks.
· STEP UP: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss, and 18.7% regardless of treatment adherence.
· SELECT trial: Once-weekly subcutaneous semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% versus placebo in patients with atherosclerotic cardiovascular disease and obesity but without diabetes.

 

A new analysis suggests this reduction cannot be fully explained by lower body weight and waist circumference alone. In the SELECT trial, semaglutide demonstrated beneficial effects on clinical outcomes and health-related quality of life irrespective of baseline frailty status.

 

Technical Specifications

· Product Name: UPMAG 5
· Peptide: Semaglutide
· Concentration: 5mg per vial
· Form: Self-mix multi-dose vial
· Reconstitution: Requires bacteriostatic water for reconstitution (2ml included)
· Administration: Once-weekly subcutaneous injection
· Supplier: Test Run Wellness (Wellness.testrun)

 

⚕️  Important Medical Notice

Please consult your medical practitioner regarding your body requirements, as the dosing information provided contains guideline dosages. UPMAG 5 is intended for use under professional medical supervision. Semaglutide is a prescription medication in many jurisdictions and should only be used under appropriate medical oversight.

Regulatory notice. Test Run Wellness is an independent supplier and is not the manufacturer of the products referenced. No product should be used without appropriate regulatory authorisation and professional medical oversight.